120 stories from 18 sources
The week in Medicine and Healthcare
Click on a headline to see stories that shaped it.
Threads
8 threads
The Democratic Republic of the Congo outbreak surpassed 10,000 cases and 5,000 deaths, while Nigeria investigated suspected cases and the response faced continuing transmission risks. The scale and lethality increased pressure for sustained treatment, surveillance, and outside support.
Lilly strengthened its position as retatrutide outperformed Ozempic in reported results and demand for Zepbound and Mounjaro lifted its outlook again. Employers, however, began dropping weight-loss coverage, showing that commercial momentum is widening access pressures.
AI moved from promising detection and administrative tools into harder questions about clinical control, liability, utilization, and market power. A lawsuit, an authorization experiment, Epic's data position, and pending regulatory coordination showed that deployment is advancing faster than governance.
Measles resurfaced as falling vaccination rates, weakened funding, and declining trust left communities vulnerable. The week's coverage connected the outbreaks to pandemic-era disruption and the need to rebuild routine immunization.
The week brought positive results across endometrial, lung, ovarian, and pancreatic cancer programs, alongside efforts to position personalized vaccines for broader use. Developers now face the next tests of regulatory review, safety, manufacturing, and commercial viability.
Open enrollment began amid changing plan choices and subsidy uncertainty, while Florida premiums surged after enhanced ACA subsidies expired. Consumers face more pressure to compare plans rather than rely on automatic renewal.
HHS moved from easing enforcement on unapproved peptides to authorizing six compounds despite objections from FDA scientists. The change could expand access quickly while leaving evidence, manufacturing, oversight, and safety standards unsettled.
Federal judges blocked or rejected narrower impairment and frailty tests for Medicaid work-requirement exemptions. The rulings preserved access for some medically vulnerable recipients and complicated implementation of the administration's policy.
Day’s Recap